-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$14.504900% Upside
Cara Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Cara Therapeutics, Inc.?
Cara Therapeutics, Inc. has been rated by research analysts at Canaccord Genuity, Stifel Nicolaus, H.C. Wainwright, Needham in the past 90 days.